NCT00613379已完成2 期
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of PRO 140 by Intravenous Administration in Adult Subjects With Human Immunodeficiency Virus Type 1 Infection
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Maximum Change in Viral Load Following Initiation of Treatment.
研究概览
简要总结
The purpose of this study is:
- To assess and characterize the PK and PD of PRO 140 administered IV
- To assess the antiviral activity of PRO 140
- To assess the safety and tolerability of PRO 140
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males & females, age ≥ 18 years (or minimum adult age as determined by local regulatory authorities)
- •Screening plasma HIV-1 RNA ≥ 5,000 copies/mL
- •CD4+ T-lymphocyte cell count ≥ 300 cells/mm3 and no documented count < or = 250 cells/mm3
- •Has not taken any anti-retroviral therapy (ART) w/in 12 wks of Early Screening Visit
- •Exclusive CCR5-tropic virus as determined by Trofile™ Assay at Early Screening Visit
- •Clinically normal or "not clinically significant (NCS)" resting electrocardiogram
- •Women of reproductive potential must have a negative serum pregnancy test at Late Screening Visit & a negative urine pregnancy test w/in 72 hrs prior to first dose of study medication, & be non-lactating. Male & female subjects must agree not to participate in a conception process from Early Screening Visit through Day 59.
排除标准
- •CXCR4 tropic virus or dual/mixed tropic (R5X4) virus determined by the Trofile™ Assay.
- •Females who are pregnant, lactating or breastfeeding, or who plan to become pregnant during the study.
- •History of active hepatitis within the previous 24 wks
- •Prior use of any entry, attachment, CCR5 co-receptor or fusion inhibitor, experimental or approved.
研究组 & 干预措施
Arm 1
Experimental
10 mg/kg PRO 140, one IV dose (N=10)
干预措施: PRO 140 (Drug)
Arm 2
Experimental
5 mg/kg PRO 140, one IV dose (N=10)
干预措施: PRO 140 (Drug)
Arm 3
Placebo Comparator
Placebo, one IV dose (N=10)
干预措施: Placebo (Drug)
结局指标
主要结局
Maximum Change in Viral Load Following Initiation of Treatment.
时间窗: 59 days
The primary end point was the maximum change from baseline in viral load following initiation of treatment, defined as HIV-1 copies/mL, measured by the Roche Amplicor HIV-1 Monitor UltraSensitive™ Test (lower limit of detection \[LLD\] = 48 copies/mL).
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety and Tolerability of PRO 140 in HIV Uninfected Male VolunteersHIV InfectionsNCT00110591CytoDyn, Inc.20
已完成
2 期
Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 InfectionHIV -1 InfectionHIV InfectionsNCT00642707CytoDyn, Inc.44
已完成
1 期
A Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC4401C in Healthy VolunteersHealthy MaleNCT01651234Green Cross Corporation48
撤回
2 期
PRO 140 for Human Immunodeficiency Virus InfectionHIVNCT02257788Drexel University
撤回
2 期
PRO 140 for Human Immunodeficiency VirusHIVNCT02438345Drexel University